# Switch From Oral Iron to Intravenous Ferric Carboxymaltose in Non-dialysis Chronic Kidney Disease (CKD)

> **NCT02232906** · PHASE4 · COMPLETED · sponsor: **Hospital Aleman** · enrollment: 30 (actual)

## Conditions studied

- Iron Deficiency
- Anaemia

## Interventions

- **DRUG:** intravenous ferric carboxymaltose

## Key facts

- **NCT ID:** NCT02232906
- **Lead sponsor:** Hospital Aleman
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2014-09-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02232906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02232906, "Switch From Oral Iron to Intravenous Ferric Carboxymaltose in Non-dialysis Chronic Kidney Disease (CKD)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02232906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*